Annual report for the Association for Accessible Medicines, formerly the Generic Pharmaceutical Association, recapping 2011. View press release to learn more about the successful rebrand.
In 2011, with the transition behind us, the Board and staff were focused on delivering a demonstrable return on investment for our member companies. When I look at our accomplishments, I can say with confidence that we have shown the value of our reinvigorated Association. We have demonstrated that together much can be achieved, and that the power of speaking with one voice and engaging across all levels of public policy and scientific regulation can generate substantial results.
Paul BisaroChairman of the Board, Generic Pharmaceutical Association
We began the year with a new look, having completed the implementation of a significant restructuring program in late 2010. Under the redesigned GPhA, a determined effort was launched to enhance the Association’s influence and effectiveness in advocating the interests of member companies. Plans called for doubling the size of the federal and state Government Affairs teams, boosting the resources allocated to legislative and regulatory initiatives, and hiring a new President and CEO with the leadership skills and experience needed to drive the message that the use of generic and biogeneric medicines is key to the sustainability of health care and of our economy. We are pleased to report that all of these milestones were reached in 2011.
As you will read in this report, we negotiated two landmark user fee programs that will help shape the future of our industry. We staved off numerous attempts to ban pro-consumer patent settlements. We led efforts to minimize shortages of critical drugs. And we continued our remarkable string of successes in the states. But those efforts represent just a fraction of our achievements.
Ralph G. NeasPresident & CEO, Generic Pharmaceutical Association